544 related articles for article (PubMed ID: 24472068)
1. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
2. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
[TBL] [Abstract][Full Text] [Related]
5. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
6. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
7. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
[TBL] [Abstract][Full Text] [Related]
8. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
9. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.
Shimada M; Yonemura Y; Ijichi H; Harada N; Shiotani S; Ninomiya M; Terashi T; Yoshizumi T; Soejima Y; Maehara Y
Transplant Proc; 2005 Mar; 37(2):1177-9. PubMed ID: 15848661
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
[TBL] [Abstract][Full Text] [Related]
12. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.
Iguchi T; Shirabe K; Aishima S; Wang H; Fujita N; Ninomiya M; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Oda Y; Maehara Y
Transplantation; 2015 Jun; 99(6):1236-42. PubMed ID: 25427164
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
17. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
19. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
